Amarin Corporation

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Amarin's mission is to create and commercialize innovative therapeutics to help prevent and treat cardiovascular and metabolic diseases, improve patient outcomes and address unmet medical needs.

Amarin's vision is to be the global leader in nanovector-based cardiovascular and metabolic therapeutics, revolutionizing the way people think about and treat cardiovascular and metabolic disease.

Amarin has won numerous awards for its successful research accomplishments in cardiovascular health and metabolic health, including the PROSE Award in Medical Science, the Outstanding Scientific Achievement Award from the American Heart Association, and the Inaugural Award for Excellence in Research from the American College of Cardiology.